Research analysts at Robert W. Baird assumed coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report released on Monday, MarketBeat reports. The brokerage set an “outperform” rating and a $27.00 price target on the stock. Robert W. Baird’s price objective points to a potential upside of 42.71% from the company’s previous close.
Separately, Canaccord Genuity assumed coverage on shares of Castle Biosciences in a research note on Monday. They issued a “buy” rating and a $26.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $26.80.
Shares of NASDAQ:CSTL opened at $18.92 on Monday. Castle Biosciences has a 52 week low of $17.11 and a 52 week high of $24.75.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Featured Article: What are gap-down stocks?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.